Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Dabrafenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,696Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis' Generic Tafinlar (Dabrafenib) Receives Approval in the U.S.
    Novartis' Generic Tafinlar (Dabrafenib) Receives Approval in the U.S.

    16 Mar 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217514

    FDA
    16 Mar 2023
    Share Share
    JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK Inhibitor
    JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK Inhibitor

    03 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230103005222/en

    BUSINESSWIRE
    03 Jan 2023
    Share Share
    Spirita Oncology, LLC Initiates a Ph1 Trial of the Anti-Cancer Agent E6201
    Spirita Oncology, LLC Initiates a Ph1 Trial of the Anti-Cancer Agent E6201

    30 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221130005871/en

    BUSINESSWIRE
    30 Nov 2022
    Share Share
    Novartis drug combo shows promise in childhood brain cancer
    Novartis drug combo shows promise in childhood brain cancer

    07 Jun 2022

    // L. Burger REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-drug-combo-shows-promise-childhood-brain-cancer-2022-06-06/

    L. Burger REUTERS
    07 Jun 2022
    Share Share
    Novartis Presents Data From PhIII Trial Of Spartalizumab With Tafinlar &Mekinist
    Novartis Presents Data From PhIII Trial Of Spartalizumab With Tafinlar &Mekinist

    20 Sep 2020

    // PRESS RELEASE

    https://www.novartis.com/news/media-releases/novartis-reports-late-breaking-data-from-phase-iii-combi-i-trial-spartalizumab-pdr001-tafinlar-and-mekinist-advanced-melanoma

    PRESS RELEASE
    20 Sep 2020
    Share Share
    Novartis' Tafinlar/Mekinist combo improves survival in new Phase 3 data
    Novartis' Tafinlar/Mekinist combo improves survival in new Phase 3 data

    17 Sep 2020

    // PHARMA FILE

    http://www.pharmafile.com/news/559508/novartis-tafinlarmekinist-combo-improves-five-year-relapse-free-survival-new-phase-3-dat

    PHARMA FILE
    17 Sep 2020
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.